CEO Total Pay
$984K
FY2022 Summary Compensation, below median
FY2022 SEC EDGAR DEF 14A
Acorda Therapeutics, Inc. CEO pay ratio
The CEO earned $984K in FY2022 against median worker pay of $196,830 · Chemicals & Pharmaceuticals.
- State
- DE
- Filing date
- 2023-04-27
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2022
Data updated August 2026
Subscribe to Acorda Therapeutics, Inc. CEO pay filing updates (RSS)
CEO-to-worker pay ratio
5:1
Below Average (Scale: 0–1000:1)
CEO pay
$984K
Median worker
$196,830
Latest filing FY2022. This company's newest DEF 14A on file is for FY2022, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Acorda Therapeutics, Inc. reported a 5:1 CEO-to-worker pay ratio in FY2022 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 5:1
- FY2022 disclosed
- CEO total
- $984K
- Summary Compensation Table total
- Median worker
- $196,830
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2022
A component-level pay breakdown is not reported in Acorda Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Filing-year trail · Acorda Therapeutics, Inc.
Complete DEF 14A pay-ratio filings for this CIK across FY2021–2022. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
- Latest ratio
- 5:1
- FY2022
- vs prior FY
- -2:1
- from FY2021 7:1
- CEO $ YoY
- -38%
- $984K latest
- Filings shown
- 2
- FY2021–2022
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2021 | $1.6M | - | $226,642 | 7:1 | - |
| 2022 | $984K | -38% | $196,830 | 5:1 | -2:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1008848, FY2021–2022. Adjacent-year deltas only.
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
5:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$984K
Companies in Industry
168
vs. Industry Median
Below
Acorda Therapeutics, Inc.: near-parity Item 402(u) ratio
Acorda Therapeutics, Inc. stamps FLOOR · ELITE-MED at 5:1 against $196,830 median worker pay in FY2022. the CEO earned 5× the median employee ($196,830) in FY2022.
At $196,830 median worker pay, the FLOOR stamp is near pay-parity territory under LIGHT CEO total.
Pay Ratio
5:1
Below typical
What FY2022 shows for Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. stamps FLOOR · ELITE-MED at 5:1 against $196,830 median worker pay in FY2022. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Acorda Therapeutics, Inc.'s $984K CEO total is at or below the $7.9M industry median CEO pay.
Acorda Therapeutics, Inc. stamps FLOOR · LIGHT · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2022
- Total Compensation
- $984K
- Median Employee Pay
- $196,830
- Pay Ratio
- 5:1
- Filing Date
- 2023-04-27
Company Info
- CIK
- 1008848
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2836
- State
- DE
SEC EDGAR DEF 14A for CIK 1008848, FY2022. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Acorda Therapeutics, Inc. stamps FLOOR · ELITE-MED at 5:1 against $196,830 median worker pay in FY2022.
Read with Acorda Therapeutics, Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · LIGHT · ELITE-MED.
AeroVironment Inc · LIGHT
ABS(ceo_total_comp) peer at $984K (Δ $639 lighter vs Acorda Therapeutics, Inc.); FLOOR · HIGH-MED vs this page's FLOOR · LIGHT · ELITE-MED.
LendingTree, Inc. · LIGHT
ABS(ceo_total_comp) peer at $986K (Δ $2K heavier vs Acorda Therapeutics, Inc.); FLOOR · HIGH-MED vs this page's FLOOR · LIGHT · ELITE-MED.
South Dakota Soybean Processors LLC · LIGHT
ABS(ceo_total_comp) peer at $978K (Δ $7K lighter vs Acorda Therapeutics, Inc.); FLOOR · HIGH-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Miller Industries Inc /tn/ · LIGHT
ABS(ceo_total_comp) peer at $972K (Δ $12K lighter vs Acorda Therapeutics, Inc.); FLOOR · PAR-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Acorda Therapeutics, Inc. stamps FLOOR · LIGHT · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · FLOOR
See where FLOOR · LIGHT packages sit on the national leaderboard after reading Acorda Therapeutics, Inc..
Ratio primer · FLOOR
Acorda Therapeutics, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Acorda Therapeutics, Inc. (CIK 1008848), FY2022. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.